Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.

Arabella S V Stuart,Miia Virta,Kristi Williams,Ilkka Seppa, Robyn Hartvickson,Melanie Greenland,Edmund Omoruyi,Arangassery Rosemary Bastian,Wouter Haazen, Nadine Salisch,Efi Gymnopoulou,Benoit Callendret,Saul N Faust,Matthew D Snape,Esther Heijnen

The Journal of infectious diseases（2022）

引用 8|浏览6

暂无评分

摘要

Ad26.RSV.preF demonstrated immunogenicity in healthy adults and toddlers, with no safety concerns raised. Evaluations in RSV-seronegative children are underway.

查看译文

关键词

adenovirus vectors,pediatric,respiratory syncytial virus,seropositive,vaccine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要